Pre- and post-engraftment bloodstream infection rates and associated mortality in allogeneic hematopoietic stem cell transplant recipients

Transplant Infectious Disease

Volumn 7, Issue 1, 2005, Pages 11-17

  Almyroudis, N G ^a,b   Fuller, A ^a,c   Jakubowski, A ^a   Sepkowitz, K ^a   Jaffe, D ^a   Small, T N ^a   Kiehn, T E ^a   Pamer, E ^a   Papanicolaou, Genovefa A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Bloodstream infection; Mortality; Rates

Indexed keywords

AMIKACIN; CEFEPIME; COTRIMOXAZOLE; FLUCONAZOLE; PENTAMIDINE; PIPERACILLIN PLUS TAZOBACTAM; TIMENTIN; VANCOMYCIN;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALPHA HEMOLYTIC STREPTOCOCCUS; ARTICLE; BLOOD FLOW; CHILD; CHRONIC MYELOID LEUKEMIA; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; ENTEROBACTERIACEAE; ENTEROCOCCUS FAECIUM; FEBRILE NEUTROPENIA; FEMALE; HEALTH SURVEY; HOSPITALIZATION; HUMAN; INFECTION; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUTROPENIA; NEUTROPHIL; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; RISK FACTOR; SEPSIS; STEM CELL TRANSPLANTATION;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MALE; MIDDLE AGED; RISK FACTORS; SEPSIS; TRANSPLANTATION, HOMOLOGOUS;

EID: 22144456755     PISSN: 13982273     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2005.00088.x     Document Type: Article

References (39)

1. BOECKH M, MARR KA. Infection in hematopoietic stem cell transplantation. In: RUBIN RH, YOUNG L eds. Clinical Approach to Infections in the Compromised Host (4th edn). New York, NY: Kluwer Academic/Plenum, 2002: 527-572.
2. CARLISLE P, GUCALP R, WIERNIK PH. Nosocomial infections in neutropenic cancer patients. Infect Control Hosp Epidemiol 1993: 14: 320-324.
3. HUGHES W, FLYNN PM, WILLIAMS BG. Nosocomial infection in patients with neoplastic disease. In: MAYHALL CG ed. Hospital Epidemiology and Infection Control. Baltimore, MD: Lippincott Williams & Wilkins, 1996: 618-631.
4. ROLSTON KVI, BODEY GP. Infections in patients with cancer. In: KUFE DW, POLLOCK RE, WEICHSELBAUM RR et al. eds. Holland-Frei Cancer Medicine. Ontario: BC Decker, 2003: 2633-2658.
5. WISPLINGHOFF H, SEIFERT H, WENZEL RP, EDMOND MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 2003: 36: 1103-1110.
6. The International Antimicrobial Therapy Cooperative Group of The European Organization For Research and Treament of Center. Gram-positive bacteremia in granulocytopenic cancer patients. Eur J Cancer 1990: 26: 569-574.
7. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 1993: 119: 584-593.
8. COLLIN B, LEATHER HL, WINGARD JR, RAMPHAL R. Evolution, incidence, and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients. Clin Infect Dis 2001: 33: 947-953.
9. MARENA C, ZECCA M, CARENINI ML, et al. Incidence of, and risk factors for, nosocomial infections among hematopoietic stem cell transplantation recipients, with impact on procedure-related mortality. Infect Control Hosp Epidemiol 2001: 22: 510-517.
10. SPARRELID E, HAGGLUND H, REMBERGER M, et al. Bacteremia during the aplastic phase after allogeneic bone marrow transplantation is associated with early death from invasive fungal infection. Bone Marrow Transplant 1998: 22: 795-800.
11. WILLIAMSON EC, MILLAR MR, STEWARD CG, et al. Infections in adults undergoing unrelated donor bone marrow transplantation. Br J Haematol 1999: 104: 560-568.
12. JAFFE D, JAKUBOWSKI A, SEPKOWITZ K, et al. Prevention of peritransplantation viridans streptococcal bacteremia with early vancomycin administration: a single-center observational cohort study. Clin Infect Dis 2004: 39: 1625-1632.
13. KIRKPATRICK B, HARRINGTON S, SMITH D, et al. An outbreak of vancomycin-dependent Enterococcus faecium in a bone marrow transplant unit. Clin Infect Dis 1999: 29: 1268-1273.
14. KLAUSNER J, ZUKERMAN C, LIMAYE A, et al. Outbreak of Stenotrophomonas maltophilia bacteremia among patients undergoing bone marrow transplantation: association with faulty replacement of handwashing soap. Infect Control Hosp Epidemiol 1999: 20: 756-758.
15. KOLBE K, DOMKIN D, DERIGS H, et al. Infectious complications during neutropenia subsequent to peripheral blood stem cell transplantation. Bone Marrow Transplant 1997: 19: 143-147.
16. SMALL T, BOULAD F, PAPADOPOULOS E, et al. Incidence and outcome of vancomycin-resistant enterococcal bacteremia following allogeneic hematopoietic stem cell transplant (HSCT). In: Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, California, September 17-30, 2002: 325 [Abstract K-1226].
17. RAAD I. Intravascular-catheter-related infections. Lancet 1998: 351: 893-898.
18. EILERS J, BERGER AM, PETERSEN MC. Development, testing, and application of the oral assessment guide. Oncol Nurs Forum 1988: 15: 325-330.
19. PAPADOPOULOS E, CARABASI M, CASTRO-MALASPINA H, et al. T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. Blood 1998: 91: 1083-1090.
20. MEIER E, ALMYROUDIS N, JAFFE D, SMALL T, SEPKOWITZ K, PAPANICOLAOU G. Fever after allogeneic HSCT: correlation with infection, engraftment and outcome. In: Program and Abstracts of the 41st Annual Meeting of the Infectious Diseases Society of America (IDSA) Chicago, September 14-17, 2003 [Abstract 332].
21. MITCHELL A, DERRINGTON P, TURNER P, et al. Gram-negative bacteremia (GNB) after 428 unrelated donor bone marrow transplants (UD-BMT): risk factors, prophylaxis, therapy and outcome. Bone Marrow Transplant 2004: 33: 303-310.
22. RUESCHER T, SODEIFI A, SCRIVANI S, et al. The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer 1998: 82: 2275-2281.
23. BOSTROM B, WEISDORF D. Mucositis and alpha-streptococcal sepsis in bone marrow transplant recipients. Lancet 1984: 1: 1120-1121.
24. RINGDEN O, HEIMDAHL A, LONNQVIST B, et al. Decreased incidence of viridans streptococcal septicemia in allogeneic bone marrow transplant recipients after the introduction of acyclovir. Lancet 1984: 1: 744.
25. BOCHUD PY, CALANDRA T, FRANCIOLI P. Bacteremia due to viridans streptococci in neutropenic patients: a review. Am J Med 1994: 97: 256-264.
26. ELTING L, BODEY GP, KEEFE BH. Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis 1992: 14: 1201-1207.
27. STEINER M, VILLABLANCA J, KERSEY J, et al. Viridans streptococcal shock in bone marrow transplantation patients. Am J Hematol 1993: 42: 354-358.
28. VILLABLANCA JG, STEINER M, KERSEY J, et al. The clinical spectrum of infections with viridans streptococci in bone marrow transplant patients. Bone Marrow Transplant 1990: 5: 387-393.
29. CARRATALA J, ALCAIDE F, FERNANDEZ-SEVILLA A, et al. Bacteremia due to viridans streptococci that are highly resistant to penicillin: increase among neutropenic patients with cancer. Clin Infect Dis 1995: 20: 1169-1173.
30. PIERARD D, DE MEYER A, LAUWERS S. Susceptibility of streptococci isolated from blood of neutropenic patients to 11 antibiotics. In: KLASTERSKI JA, ed. Febrile Neutropenia. New York: Springer-Verlag Telos, 1997: 8: 57-58.
31. SHENEP J, HUGHES W, ROBERSON P, et al. Vancomycin, ticarcillin, and amikacin compared with ticarcillin-clavulanate and amikacin in the empirical treatment of febrile, neutropenic children with cancer. N Engl J Med 1988: 319: 1053-1058.
32. HUGHES W, ARMSTRONG D, BODEY G, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002: 34: 730-751.
33. COMETTA A, KERN WV, DE BOCK R, et al. Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis 2003: 37: 382-389.
34. GOODMAN J, WINSTON D, GREENFIELD R, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992: 326: 845-851.
35. SLAVIN MA, OSBORNE B, ADAMS R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis 1995: 171: 1545-1552.
36. ROTSTEIN C, Bow E, LAVERDIERE M, et al. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin Infect Dis 1999: 28: 331-340.
37. MARR K, SEIDEL K, WHITE T, et al. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000: 181: 309-316.
38. MARR K, SEIDEL K, SLAVIN M, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000: 96: 2055-2061.
39. YADEGARYNIA D, TARRAND J, RAAD I, et al. Current spectrum of bacterial infections in patients with cancer. Clin Infect Dis 2003: 37: 1144-1145.